MedStar Authors catalog › Details for: A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials.
Normal view MARC view ISBD view

A comparison of the ultrathin Orsiro Hybrid sirolimus-eluting stent with contemporary drug-eluting stents: A meta-analysis of randomized controlled trials.

by Lipinski, Michael J; Forrestal, Brian J; Iantorno, Micaela; Torguson, Rebecca; Waksman, Ron.
Citation: Cardiovascular Revascularization Medicine. 19(1 Pt A):5-11, 2018 01..Journal: Cardiovascular revascularization medicine : including molecular interventions.Published: ; 2018ISSN: 1878-0938.Full author list: Lipinski MJ; Forrestal BJ; Iantorno M; Torguson R; Waksman R.UI/PMID: 29221958.Subject(s): Aged | *Cardiovascular Agents/ad [Administration & Dosage] | Cardiovascular Agents/ae [Adverse Effects] | Coronary Artery Disease/dg [Diagnostic Imaging] | Coronary Artery Disease/mo [Mortality] | Coronary Artery Disease/pp [Physiopathology] | *Coronary Artery Disease/su [Surgery] | Coronary Thrombosis/et [Etiology] | Coronary Vessels/dg [Diagnostic Imaging] | Coronary Vessels/pp [Physiopathology] | *Coronary Vessels/su [Surgery] | *Drug-Eluting Stents | Female | Humans | Male | Middle Aged | Myocardial Infarction/et [Etiology] | Percutaneous Coronary Intervention/ae [Adverse Effects] | *Percutaneous Coronary Intervention/is [Instrumentation] | Percutaneous Coronary Intervention/mo [Mortality] | Prosthesis Design | Randomized Controlled Trials as Topic | Risk Factors | *Sirolimus/ad [Administration & Dosage] | Sirolimus/ae [Adverse Effects] | Time Factors | Treatment OutcomeInstitution(s): MedStar Heart & Vascular Institute | MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.carrev.2017.11.009 (Click here) Abbreviated citation: Cardiovasc Revasc Med. 19(1 Pt A):5-11, 2018 01.Local Holdings: Available in print through MWHC library: 2002 - present.Abstract: BACKGROUND: Recent studies suggest the Orsiro sirolimus-eluting stent (O-SES), which has ultrathin struts with a biodegradable sirolimus-eluting polymer coating, performed better than contemporary drug-eluting stents (DES). We performed a meta-analysis to compare clinical outcomes for all randomized controlled trials (RCTs) of O-SES vs contemporary DES.Abstract: METHODS/MATERIALS: PubMed, Cochrane CENTRAL, and meeting abstracts were searched for all RCTs comparing O-SES with contemporary DES. Pooled estimates of longest available clinical outcomes at a minimum of one-year follow-up, presented as odds ratios (OR) [95% confidence intervals], were generated with random-effect models.Abstract: RESULTS: We included 8 RCTs with a total of 11,176 patients (5444 O-SES and 5732 contemporary DES [3537 EES, 1295 ZES, and 1264 BP-BES) with a mean age of 65+/-11, 74% were male, 40% underwent PCI for stable angina, and 56% for ACS. We assessed outcomes comparing O-SES vs. everolimus-eluting stents, vs. permanent-polymer DES, and vs. all DES including biodegradable-polymer DES. Orsiro performed comparably in all categories with a trend toward a reduction in myocardial infarction (0.83 [0.68, 1.02], p=0.07) and stent thrombosis (0.75 [0.54, 1.04], p=0.08).Abstract: CONCLUSION: Overall, the Orsiro SES had similar clinical outcomes to contemporary DES with a trend toward reduction in myocardial infarction and stent thrombosis.Abstract: Copyright (c) 2017 Elsevier Inc. All rights reserved.

Powered by Koha